ScoreWhy is TherapeuticsMD, Inc. ?
1
Poor long term growth as Operating profit has grown by an annual rate 14.69% of over the last 5 years
2
With a growth in Operating Profit of 11.75%, the company declared Very Positive results in Mar 26
- The company has declared positive results for the last 7 consecutive quarters
- OPERATING CASH FLOW(Y) Highest at USD 2.68 MM
- PRE-TAX PROFIT(Q) At USD 0.1 MM has Grown at 186.37%
- NET PROFIT(Q) At USD 0.1 MM has Grown at 186.37%
3
With ROE of 0.73%, it has a attractive valuation with a 0.89 Price to Book Value
- Over the past year, while the stock has generated a return of 80.18%, its profits have risen by 107.4% ; the PEG ratio of the company is 0.2
4
High Institutional Holdings at 33.4%
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
- Their stake has increased by 3.07% over the previous quarter.
5
Market Beating Performance
- The stock has generated a return of 80.18% in the last 1 year, much higher than market (S&P 500) returns of 22.24%
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to TherapeuticsMD, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is TherapeuticsMD, Inc. for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
TherapeuticsMD, Inc.
80.18%
-0.05
76.50%
S&P 500
22.24%
1.67
13.28%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
-46.28%
EBIT Growth (5y)
14.69%
EBIT to Interest (avg)
-4.73
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.18
Sales to Capital Employed (avg)
0.28
Tax Ratio
2.86%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
33.40%
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
24
Industry P/E
Price to Book Value
0.89
EV to EBIT
-6.97
EV to EBITDA
-8.18
EV to Capital Employed
0.85
EV to Sales
6.53
PEG Ratio
0.23
Dividend Yield
NA
ROCE (Latest)
-12.24%
ROE (Latest)
0.73%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
Bearish
Bollinger Bands
Sideways
Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bullish
Mildly Bearish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend23What is working for the Company
OPERATING CASH FLOW(Y)
Highest at USD 2.68 MM
PRE-TAX PROFIT(Q)
At USD 0.1 MM has Grown at 186.37%
NET PROFIT(Q)
At USD 0.1 MM has Grown at 186.37%
NET SALES(HY)
At USD 1.62 MM has Grown at 52.55%
ROCE(HY)
Highest at 0.32%
DEBT-EQUITY RATIO
(HY)
Lowest at -9.59 %
DEBTORS TURNOVER RATIO(HY)
Highest at 1.08 times
OPERATING PROFIT(Q)
Highest at USD -0.4 MM
-1What is not working for the Company
RAW MATERIAL COST(Y)
Grown by 27.69% (YoY
Here's what is working for TherapeuticsMD, Inc.
Pre-Tax Profit
At USD 0.1 MM has Grown at 186.37%
over average net sales of the previous four periods of USD -0.12 MMMOJO Watch
Near term Pre-Tax Profit trend is very positive
Pre-Tax Profit (USD MM)
Net Profit
At USD 0.1 MM has Grown at 186.37%
over average net sales of the previous four periods of USD -0.12 MMMOJO Watch
Near term Net Profit trend is very positive
Net Profit (USD MM)
Operating Cash Flow
Highest at USD 2.68 MM and Grown
In each year in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (USD MM)
Net Sales
At USD 1.62 MM has Grown at 52.55%
Year on Year (YoY)MOJO Watch
Near term sales trend is positive
Net Sales (USD MM)
Debt-Equity Ratio
Lowest at -9.59 % and Grown
In each half year in the last five Semi-Annual periodsMOJO Watch
The company has been reducing its borrowing as compared to equity capital
Debt-Equity Ratio
Debtors Turnover Ratio
Highest at 1.08 times and Grown
In each half year in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its Debtors faster
Debtors Turnover Ratio
Operating Profit
Highest at USD -0.4 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (USD MM)
Here's what is not working for TherapeuticsMD, Inc.
Raw Material Cost
Grown by 27.69% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin
Raw Material Cost as a percentage of Sales
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
